A further reinforcement of the pathogenicity of a heterozygous gain of dosage of PCDH19 comes from the fact that this mechanism has already been described in craniofrontonasal syndrome (CFNS). This evidence concerns the gene PCDH19 and Craniofrontonasal dysplasia.